Browse Studies — Arctuva

Phase 1

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS). Primary Objectives Intermediate-Risk * To estimate the 3-year event-free surviva…

Adipocytic NeoplasmLiposarcomaAtypical Fibroxanthoma+39 more

Estimated

~$10 – $6,250

St. Jude Children's Research HospitalNCT06239272

Real-World Patient Experience of Vimseltinib for the Treatment of Tenosynovial Giant Cell Tumor (MOVE)

The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participa…

Tenosynovial Giant Cell Tumor

Estimated

~$10 – $1,050

Deciphera Pharmaceuticals, LLCNCT07075471

Phase 1

A Phase 1, Open-Label Study of ABSK021 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumor

This is an open-label phase 1 study to determine the safety and tolebility of oral ABSK021 in patients with advanced solid tumor as well as the Recommended Pha…

NeoplasmsTenosynovial Giant Cell Tumor

Estimated

~$10 – $8,750

Abbisko Therapeutics Co, LtdNCT04192344

A Long-term Study to Further Evaluate the Risk of Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment

A study to evaluate the long-term risk of hepatic failure with TURALIO™ (pexidartinib) and the mechanism of liver injury based upon optional liver biopsy infor…

HepatotoxicityTenosynovial Giant Cell Tumor

Estimated

~$10 – $1,125

Daiichi SankyoNCT04635111